Key takeaways
- In the US, UK and Australia, regulators decide what a peptide is by how it is presented and sold, not by its label alone.
- US: since 28 October 2026, HHS says it will not act against licensed pharmacies and physicians compounding six peptides under ten conditions; it is not an approval.
- UK: a peptide presented or used as a medicine needs authorisation, and the MHRA has said it disregards “research purposes” claims used to avoid that.
- Australia: the TGA says supplying unapproved peptides is unlawful; BPC-157 and TB-500 are Schedule 4 and illegal to possess without authority.
- Sport: BPC-157 and TB-500 are prohibited at all times under the WADA List.
01The one idea that decides it
In all three markets, the law looks at what a product is for, not only at what it is called.
United States. FDA judges a product’s intended use from objective evidence: labelling, advertising, statements and the circumstances of the sale. A peptide intended for use in people without FDA approval is an unapproved new drug.
United Kingdom. A product is a medicinal product if it is presented as treating or preventing disease, or used to modify a physiological function by a pharmacological action. An unauthorised medicinal product may not be sold or supplied.
Australia. Peptide products supplied for therapeutic use are regulated as therapeutic goods. Those not on the Australian Register of Therapeutic Goods are unapproved, and the TGA says supplying them is unlawful.
02Market by market
One table, three markets. Each row links to a full page with the primary documents.
| Market | A “research use only” label | Sold for use in people | What regulators did in 2026 | Full page |
|---|---|---|---|---|
| United States | FDA’s 2026 warning letters said such labels did not outweigh website evidence of human use. | Unapproved new drug, unless FDA-approved or lawfully compounded. | HHS (28 Oct): no enforcement against licensed compounding of six peptides under ten conditions. FDA warning letters to RUO sellers. | US |
| United Kingdom | The MHRA has said it disregards “research purposes” claims used to avoid medicines rules (reported, Mar 2026). | Unauthorised medicinal product under the Human Medicines Regulations 2012. | MHRA said it disregards “research purposes” claims used to avoid medicines rules (Mar). | UK |
| Australia | The TGA says such disclaimers do not make supply lawful or permit importation. | Unlawful to import, advertise, manufacture or supply unapproved peptides. BPC-157 and TB-500 are Schedule 4. | Safety advisory on research-use claims (Apr); seizures and a public statement that supplying unapproved peptides is unlawful (Aug). | Australia |
| European Union (context) | Not tracked on this site. | Medicinal product needing authorisation (Directive 2001/83/EC, Art. 1). | Not tracked market by market on this site. | — |
For BPC-157 specifically, with a dated timeline across all three markets, see is BPC-157 legal?
03Sport is a separate rulebook
Anti-doping rules apply to athletes whatever national law says. WADA’s Prohibited List names BPC-157 in class S0, non-approved substances, which covers any pharmacological substance with “no current approval by any governmental regulatory health authority for human therapeutic use”. It lists thymosin-β4 and its derivatives, such as TB-500, under S2.3. Both are prohibited at all times, and a national compounding policy does not change that. Detail: peptides and anti-doping.
04Where to go next
Market pages: United States · United Kingdom · Australia.
By topic: is BPC-157 legal? · research use only · the 2026 FDA advisory vote · the HHS policy.
What changed, when: the regulatory changelog records dated regulatory events, newest first.
Laws change, and this page is dated for that reason. What we don’t know: whether FDA will list any peptide through rulemaking, how long the US enforcement policy will last, and how state and territory rules in the US and Australia will apply to specific cases.
This is a plain-English summary of public documents, checked on 17 Nov 2026. It is not legal advice.